Abstracts tagged "Bioinformatics"

Abstract Number: 0131 • ACR Convergence 2023
Identifying Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease: Development and Validation of a Real-Time Risk Model
April Barnado, Ryan Moore, Hank Domenico, Sarah Green, Alex Camai, Ashley Suh, Bryan Han, Katherine Walker, Audrey Anderson, Lannawill Caruth, Anish Katta, Allison McCoy and Daniel W. Byrne, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Up to 20% of the general population has a positive ANA without having autoimmune disease. Currently, no tools exist to help clinicians interpret the…
Abstract Number: 0922 • ACR Convergence 2023
The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles
Tomás Cerdó¹, Carlos Perez-Sanchez², Laurel Woodridge³, Mª Angeles Aguirre⁴, Rafaela Ortega Castro⁵, Ismael Sánchez-Pareja⁶, Laura Muñoz-Barrera¹, Pedro Segui¹, Christian Merlo⁶, Pedro Ortiz Buitrago⁷, Desiree Ruiz Vilchez⁸, Maria del Carmen Abalos-Aguilera⁸, Pilar Font Ugalde¹, Nuria Barbarroja⁹, Alejandro Escudero¹⁰, Elizabeth Jury³ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁵Hospital Reina Sofía, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁹University of Cordoba, Córdoba, Spain, ¹⁰SAS, Córdoba, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) poses a significant challenge at the diagnostic and treatment levels due to its severe multisystem nature and notable heterogeneity in…
Abstract Number: 1661 • ACR Convergence 2023
Spatial Transcriptional Alterations in the Cellular Landscape of Pediatric Scleroderma Skin
Kathryn Torok¹, Ying-Ju Lai², Zhongli Xu³, Anwesha Sanyal³, Giffin Werner³, Theresa Hutchins³, Claire Cheng³ and Wei Chen³, ¹University of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittbsurgh, Pittsburgh, PA, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Recent single-cell RNA sequencing (scRNA seq) data has been generated across several tissues in autoimmune diseases, helping to understand the cellular and molecular underpinnings…
Abstract Number: 2515 • ACR Convergence 2023
Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura⁵ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…
Abstract Number: 0132 • ACR Convergence 2023
Feasibility of a Real-Time Risk Model to Identify Antinuclear Antibody Positive Individuals at Risk for Systemic Autoimmune Disease
April Barnado, Ryan Moore, Hank Domenico, Sarah Green, Alex Camai, Ashley Suh, Bryan Han, Katherine Walker, Audrey Anderson, Lannawill Caruth, Anish Katta, Allison McCoy and Daniel W. Byrne, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across multiple specialties. We previously developed and validated a risk model using a de-identified electronic…
Abstract Number: 0926 • ACR Convergence 2023
Single-cell Multi-Omic Evaluation of Differences in Immune Cell Populations in Progression Toward Systemic Lupus Erythematosus
Aleksandra Bylinska, Miles Smith, Samantha Slight-Webb, Carla Guthridge, Caleb Marlin, Kevin Thomas, Christian Wright, Marci Beel, Susan Macwana, Wade DeJager, Judith James and Joel Guthridge, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Several groups of individuals are at higher risk for SLE, including those with African American ancestry (AA), lupus-associated autoantibodies (ANA+), or some clinical symptoms…
Abstract Number: 1668 • ACR Convergence 2023
Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes
Monica Yang¹, Fred Deiter¹, Emily Flynn¹, Jessica Neely¹, Seoyeon Lee², John Greenland¹, Marina Sirota³ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA
Background/Purpose: Interstitial lung disease (ILD) is present in up to 90% of patients with systemic sclerosis (SSc) and the leading cause of SSc-related mortality. SSc-ILD…
Abstract Number: 2526 • ACR Convergence 2023
Single-cell RNA Sequencing Reveals the CRTAC1+ Population Actively Contributes to the Pathogenesis of Spinal Ligament Degeneration by Inducing Macrophage Activation
Yulong Tang¹, Dachun Zhuo¹, Li Jin¹, Qi Zhu², Yuanyuan Chen³, Jiucun Wang⁴ and Jing Liu⁴, ¹Fudan University, Shanghai, China, ²Guanghua Integrative Medicine Hospital, Shanghai, China, ³Shanghai Sixth People's Hospital, Shanghai, China, ⁴Shanghai, Shanghai, China
Background/Purpose: Spinal ligament degeneration is a chronic disease that affects the spine, ligaments, and associated bones, resulting in back pain and functional limitations in the…
Abstract Number: 0185 • ACR Convergence 2023
Classifying Individuals with Rheumatic Conditions as Financially Insecure Using Electronic Health Record Data and Natural Language Processing: Algorithm Derivation and Validation
Mia Chandler¹, Tianrun Cai², Leah Santacroce², Sciaska Ulysse², Katherine Liao² and Candace Feldman², ¹Boston Children's Hospital, Milton, MA, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Social determinants of health (SDoH) such as financial insecurity contribute to disparities in rheumatic disease care and outcomes but are not routinely included in…
Abstract Number: 0938 • ACR Convergence 2023
Deconvolution of the Molecular Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: A Biomarker Blueprint of Scleroderma Disease Continuum
Sunhwa Kim¹, Thierry Sornasse², Vishal Kakkar³, Rebecca Ross⁴, Yingtao Bi⁵, Hengcheng Hu², Lisa Hazelwood², Lauren Reinke-Breen⁶, jozsef karman⁷, Chris Butler², Jennifer Van Camp² and Francesco Del Galdo⁸, ¹AbbVie, Inc., South San Francisco, CA, ²AbbVie, Inc., North Chicago, IL, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵AbbVie, Inc., Worcester, MA, ⁶AbbVie, Inc., Vernon Hills, IL, ⁷AbbVie, Inc., San Francisco, CA, ⁸University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease that affects multiple organs asynchronously, leading to highly variable fibrotic damage and consequent increased morbidity and mortality.…
Abstract Number: 1697 • ACR Convergence 2023
Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
Ioannis Parodis¹, Julius Lindblom¹, Guillermo Barturen², Rafaela Ortega Castro³, Ricard Cervera⁴, Jacques-Olivier Pers⁵, Fernanda Genre Romero⁶, Falk Hiepe⁷, Maria Gerosa⁸, Laszlo Kovacs⁹, Ellen De Langhe¹⁰, Silvia Piantoni¹¹, Georg Stummvoll¹², Carlos Vasconcelos¹³, Barbara Vigone¹⁴, Torsten Witte¹⁵, Marta Alarcon-Riquelme¹⁶ and Lorenzo Beretta¹⁷, ¹Karolinska Institutet, Stockholm, Sweden, ²Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Centre Hospitalier Universitaire de Brest, Hospital de la Cavale Blanche, Brest, France, ⁶IDIVAL, Santander, Spain, ⁷Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁸University of Milan, Milano, Italy, ⁹University of Szeged, Szeged, Hungary, ¹⁰Katholieke Universiteit Leuven and Universitair Ziekenhuis Leuven, Leuven, Belgium, ¹¹ASST Spedali Civili and University of Brescia, Brescia, Italy, ¹²Medical University Vienna, Baden, Austria, ¹³Centro Hospitalar do Porto, Porto, Portugal, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, ¹⁵Dept of Immunology and Rheumatology, Hannover, Germany, ¹⁶Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Italy
Background/Purpose: Treating to remission or lupus low disease activity state (LLDAS) are conceptual frameworks for the management of SLE, but the biological milieus underlying these…
Abstract Number: 2540 • ACR Convergence 2023
The Molecular Stratification of Rheumatoid Arthritis Using High-throughput Technologies Is Directly Associated with Disease Activity and Clinical Response
Ismael Sanchez-Pareja¹, Daniel Toro-Dominguez², Carlos Perez-Sanchez³, Laura Muñoz-Barrera¹, Tomás Cerdó¹, Rafaela Ortega Castro⁴, Jerusalem Calvo⁵, Marta Rojas⁶, Pilar Font Ugalde¹, Maria del Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez¹, Christian Merlo-Ruiz¹, Ivan Arias de la Rosa⁸, Mª Angeles Aguirre⁹, Eduardo Collantes Estévez¹⁰, Nuria Barbarroja¹¹, Marta Alarcon-Riquelme¹², Alejandro Escudero Contreras⁵ and Chary Lopez-Pedrera¹³, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²GENYO, Granada, Spain, ³IMIBIC, Córdoba, Spain, ⁴Hospital Reina Sofía, Cordoba, Spain, ⁵Reina Sofia University Hospital, Córdoba, Spain, ⁶Hospital Universitario Reina Sofía, Cordoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ⁹Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ¹⁰Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹¹University of Cordoba, Córdoba, Spain, ¹²Center for Genomics and Oncological Research (GENYO), Granada, Spain, ¹³IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a remarkably heterogeneous autoimmune disease whose clinical outcomes with disease-modifying antirheumatic drugs (DMARDs) remain unpredictable. The aim of this study…
Abstract Number: 0243 • ACR Convergence 2023
Decreased Incidence of Gout After Kidney Transplant over the Last Decade: An Analysis from a Large Academic Renal Transplant Center
Nishah Panchani¹, Angelo Gaffo² and Vineeta Kumar³, ¹Tinsley Harrison Internal Medicine Residency Program, University of Alabama at Birmingham, Arlington, TX, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL, ³Division of Nephrology/Transplant, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout has been associated with high rates of morbidity and mortality in kidney transplant (KT) patients with increased bone destruction and associated cardiovascular and…
Abstract Number: 0948 • ACR Convergence 2023
Nintedanib Alters Fibroblast and Macrophage Diversity in a 3D Skin Model of Systemic Sclerosis (SSc)
Noelle Kosarek¹, Tamar Abel², Sasha Shenk³, Tammara Wood², Jonathan Garlick⁴, Patricia Pioli⁵ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Tufts University, Boston, MA, ⁴Tufts University School of Dental Medicine, Boston, MA, ⁵Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs. While the tyrosine kinase inhibitor Nintedanib is…
Abstract Number: 1710 • ACR Convergence 2023
Genetic Associations in Juvenile Idiopathic Arthritis Determined with an Electronic Health Record Based Approach
Elizabeth Jasper, Srushti Gangireddy, Henry Ong, Jacklyn Hellwege, Todd Edwards, Digna Velez Edwards, Wei-Qi Wei and Anna Patrick, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses multiple forms of pediatric autoimmune arthritis. Research studies in JIA are complicated by disease heterogeneity and difficulties gathering large…

« Previous Page
1
…
8
9
10
11
12
…
21
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].